Skip to content
Learn Motion
ExploreHow it worksMembership
Log in
Learn Motion

How AI Makes Clinical Trials Faster: A High-Level Overview

1Why Clinical Trials Are Slow, and Where AI Fits In2Faster Study Design and Protocol Planning3Finding and Enrolling Participants Sooner4Keeping Participants in the Trial5Monitoring Data and Catching Problems Early6Analyzing Results and Reporting Sooner7What the Time Savings Add Up To, and What AI Cannot Fix
Why Clinical Trials Are Slow, and Where AI Fits In

The Journey From Idea to Approved Treatment

1 / 4
Look at the timeline as one continuous strip. Each band is a stage of the trial, and its width is how long that stage usually takes. Design comes first, then the three phases of testing in people, then analysis and reporting. Notice that the bands are not equal: the later phases are much wider, and the whole strip stretches across many years. That width is the thing we are trying to shrink.
0:00 / 0:00

A clinical trial is the part of medical research where a treatment is tested in people, and it sits inside a longer journey. The journey usually begins with laboratory and animal work, then moves into testing in humans, and ends with regulatory review before a treatment reaches patients.

The human-testing portion is conventionally divided into three phases. Phase 1 uses a small number of participants, often a few dozen, and lasts several months; its purpose is mainly to check safety and find a tolerable dose. Phase 2 uses a few hundred participants and typically runs one to two years, looking at whether the treatment seems to work and continues to be safe. Phase 3 is the largest, often involving hundreds to several thousand participants across many sites, and commonly takes two to four years.

Around these phases sit two other blocks of work. Before any phase begins, the trial must be designed and its protocol written. After the last participant finishes, the data must be analyzed and the results reported. Adding the phases together with design, analysis, and reporting, a typical development program spans roughly six to twelve years, and the surrounding regulatory review can add more.

The important point is not the exact numbers, which vary widely by disease and treatment, but the shape of the timeline: a long, mostly sequential chain in which each stage waits for the one before it.

1 / 4Next

Learn Motion

Generate a course. Learn it properly.

Operated by Wuhan Daoyin Technology Co., Ltd.

Contact: [email protected]
Privacy PolicyTerms of Service

© 2026 Learn Motion